What is Adenovirus Vector Vaccine?
Adenovirus represents the class of the genetically diverse DNA viruses that can cause non-life-threatening infections related to eyes, respiratory system, gastrointestinal lining and other parts. These viruses represent promising results as a vector for delivering target antigens to various hosts due to excellent ability induce immune response. Due to these property, the new studies concluded positive results for use of adenovirus for both gene therapy and vaccine production. Adenovirus-based vectors shows various benefits when compared to other viral vectors such as wide range of tissue tropism, ease of genetic manipulation especially for large transgene DNA insertions, superior ability to induce robust transgene-specific T cell and antibody responses, easy production of the adenovirus based vaccines at large scale. Due to this, it has emerged as a preferred choice for delivering vaccine for both humans as well as animals.
The market study is broken down by Type (Adenovirus-based tuberculosis vaccine, Adenovirus-based HIV vaccine, Adenovirus-based influenza vaccine and Others), by Application (Human and Animals) and major geographies with country level break-up.
Creative Biolabs (United States), Sartorius AG (Germany), Lonza (Switzerland), Merck KGaA (Germany), Cobra Biologics (United States), Thermo Fisher Scientific (United States), Boehringer Ingelheim (Germany), Oxford Biomedica (United Kingdom) and Advanced Bioscience Laboratories (United States) are some of the key players that are part of study coverage.
AdvanceMarketAnalytics has segmented the market of Global Adenovirus Vector Vaccine market by Type, Application and Region.
On the basis of geography, the market of Adenovirus Vector Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-user, the sub-segment i.e. Hospitals will boost the Adenovirus Vector Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Leaders and their expansionary development strategies
In January 2021, Thermo Fisher Scientific, a company offering range of instrumentation, reagents and consumables, and software and services acquired the viral-vector manufacturing business of the Novasep, a pharmaceutical company for approximately USD 875 million in cash. This acquisition is a step towards expanding Thermo Fisher capabilities in the cell and gene vaccines and therapies worldwide.
In June 2020, the Oxford Biomedica plc signed a Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre for collaborative working on scaling-up the GMP manufacture of the adenovirus vector based COVID-19 vaccine candidate, AZD1222 (previously known as ChAdOx1 nCoV-19), which has entered clinical trials at multiple sites in the UK.
In February 2021, the Janssen Biotech, a part of Johnson and Johnson submitted Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA), for its investigational single-dose coronavirus 2019 (COVID-19) vaccine candidate. The vaccine Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein
- Increasing investment in vaccine and drug development
- Rising collaboration between the pharmaceutical companies and CROs for development of adenovirus vector vaccine
- Growing prevalence of chronic medical conditions
- Rise in demand for efficient vaccines to treat infectious diseases
- Emergence of adenovirus vectored vaccines for COVID-19
- Production of low cost adenovirus vaccines
Key Target Audience
Manufacturers of Viral Vector Vaccines, Contract Research Organization and Governmental bodies
During this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase